

Synthesis, X-ray and Fluorescence Characteristics of Pyrimido[5,4-*e*]thiazolo[3,2-*a*]pyrimidine as a Novel Heterocyclic System

Zahra Ebrahimpour¹ · Mehdi Bakavoli¹ · Ali Shiri¹ · Seyed Mohammad Seyedi¹ · Tayebe Asghari¹ · Joel T. Mague²

Received: 16 November 2016 / Accepted: 19 February 2017 / Published online: 10 March 2017
© Springer Science+Business Media New York 2017

Abstract Derivatives of a new heterocyclic system, pyrimido[5,4-*e*]thiazolo[3,2-*a*]pyrimidine **3**, were prepared by sequential treatment of ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate **1** with 4,5-dihydrothiazol-2-amine **2** and various secondary amines. Single crystal X-ray analysis confirmed the structure of the regioisomer **3**. The photophysical characterization of these new compounds was performed by UV/VIS absorption and fluorescence emission spectroscopy. Out of six derivatives studied, only four products **4a–d** showed relatively strong fluorescence intensity. The relevant photophysical parameters for all derivatives in this series, including quantum yields and Stokes shifts for the best fluorophores are given.

Keyword Pyrimidothiazolopyrimidine · X-ray · Heterocyclization · Fluorescence spectroscopy

Introduction

Pyrimidopyrimidines as an important fused heterocyclic system have interested a great concern due to their wide range of biological activities [1–3]. The literature surveys revealed us they have been used as antitumor [4], antiviral [5], antifungal [6], antimicrobial [7] and antiplatelet [8] agents along with potent inhibitors of the tyrosine kinase

domain of epidermal growth factor receptor [9] and 5-phosphoribosyl-1-pyrophosphate synthetase [10]. The [3 + 3] ring closure of 2-aminopyrimidines with a variety of bifunctional electrophiles [11, 12] as well as the treatment of 4,6-dichloro-5-formylpyrimidine with primary amines and aldehydes [13] are the most common synthetic pathways to pyrimidopyrimidines.

In addition, thiazolopyrimidines have been reported to display a range of significant biological properties such as calcium channel and CXCR2 receptor antagonists [14], antitumor, antimetastatic and antiinflammatory agents [15]. The synthesis of thiazolopyrimidines have been achieved via the reaction of 2-thiouracil with ethyl γ -chloroacetoacetate [16] or 1,2-dibromoethane [17] and intramolecular cyclization of 1-(2-hydroxyethyl)-thiouracil with mesyl chloride [18]. The other strategies involve the cyclization of 2-amino-2-thiazoline with ethoxymethylenemalonic esters [19], diketenes [20], acetylene dicarboxylic esters [21] and ethyl malonyl chlorides [22].

In conjunction with our previous work based on the synthesis of new heterocyclic compounds with interesting pharmacological and fluorescent properties [23–26], we wish to report the synthesis of several derivatives of pyrimido[5,4-*e*]thiazolo[3,2-*a*]pyrimidine as a novel heterocyclic system together with evaluation of their photophysical properties through their UV/Vis absorption and fluorescence emission spectra.

✉ Mehdi Bakavoli
mbakavoli@um.ac.ir; mbakavoli@yahoo.com

¹ Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad 91775-1436, Iran

² Department of Chemistry, Tulane University, New Orleans, LA 70118, USA

Experimental

Melting points were taken on an Electrothermal type 9200 melting point apparatus and are uncorrected. The IR spectra were obtained in KBr disks on an Avatar 370 FT-IR Thermo-

Nicolet spectrometer (ν_{\max} in cm^{-1}). The ^1H NMR spectra were recorded on a Bruker AC at 300 MHz using tetramethylsilane (TMS) as an internal reference. Chemical shift values were given in ppm downfield from TMS. The Mass spectra were obtained on a Varian Mat CH-7 instrument at 70 eV. Elemental analysis was performed on a Thermo Finnigan Flash EA microanalyzer. A hemisphere of X-ray data was collected on a Bruker D8 Venture Photon 100 diffractometer using ω scans under control of the APEX2 [27] software package. Raw intensities were reduced to F^2 values with SAINT [27] which also performed a global refinement of unit cell parameters. Absorption corrections and merging of equivalent reflections was carried out with SADABS [27] and the structure solved by a combination of Patterson and direct methods (SHELXT [27]). The structure was refined by full-matrix, least-squares methods (SHELX-2014 [28]) with hydrogen atoms attached to carbon placed in calculated positions and that attached to nitrogen placed in a location derived from a difference map and adjusted to give N–H = 0.91 Å. All hydrogen atoms were included as riding atoms with isotropic displacement parameters tied to their attached atoms.

2-(Methylthio)-7,8-dihydro-5H-pyrimido[5,4-e]thiazolo[3,2-a]pyrimidin-5-one (3)

To a solution of 2-aminothiazole **1** (1 mmol, 0.1 g) and Et_3N (1.5 mmol, 0.2 ml) in CH_3CN (10 mL), ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate **2** (1 mmol, 0.23 g) was added. The solution was stirred for 2 h at room temperature. The resulting precipitate was filtered off, washed with water (2×50 mL) and dried. Yield = 80%, mp = 247–250 °C, ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 2.57 (s, 3H, CH_3), 3.64 ppm (t, $J = 7.8$ Hz, 2H, CH_2), 4.58 ppm (t, $J = 7.8$ Hz, 2H, CH_2), 8.98 (s, 1H, CH-pyrimidine). ^{13}C NMR (75 MHz, DMSO) 14.4, 27.0, 49.1, 106.2, 155.3, 158.5, 166.4, 172.5, 176.3. IR

(KBr disc, cm^{-1}) ν 3039, 2970, 2929, 1659, 1584. MS (m/z) 252 (M^+). Anal. Calcd. for $\text{C}_9\text{H}_8\text{N}_4\text{OS}_2$: % C, 42.84; H, 3.20; N, 22.21; S, 25.41. Found C, 42.76; H, 3.35; N, 22.12; S, 25.59.

General Procedure for the Preparation of Compounds (4a–f)

The appropriate secondary amine (30 mmol) was added to a stirred mixture of compound **3** (1 mmol, 0.25 g) in acetonitrile (10 mL), and the solution was heated under reflux for 3 h. The progress of the reaction was monitored by TLC using $\text{CHCl}_3:\text{MeOH}$ (20:1). The solid obtained on cooling was filtered and recrystallized from ethanol.


2-(Pyrrolidin-1-yl)-7,8-dihydro-5H-pyrimido[5,4-e]thiazolo[3,2-a]pyrimidin-5-one (4a)

White powder, yield = 55%, mp = 294–298 °C, ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 1.96 (m, 4H, 2CH_2), 3.48 (m, 6H, $2\text{CH}_2\text{N}$ and 2CH_2), 4.47 (t, $J = 7.2$ Hz, 2H, 2CH_2), 8.78 ppm (s, 1H, pyrimidine). ^{13}C NMR (75 MHz, DMSO) 26.7, 43.9, 46.1, 48.7, 100.8, 156.5, 160.6, 161.3, 166.6, 171.1. IR (KBr disc) ν 3132, 3088, 2958, 2873, 1677, 1586 cm^{-1} . MS (m/z) 275 (M^+). Anal. Calcd. for $\text{C}_{12}\text{H}_{13}\text{N}_5\text{OS}$: % C, 52.35; H, 4.76; N, 25.44; S, 11.64. Found C, 52.22; H, 4.89; N, 25.46; S, 11.94.

2-(Piperidin-1-yl)-7,8-dihydro-5H-pyrimido[5,4-e]thiazolo[3,2-a]pyrimidin-5-one (4b)

White powder, yield = 73%, mp. = 147–150 °C, ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 1.56 (m, 2H, CH_2), 1.67 (m, 4H, 2CH_2), 3.57 (t, $J = 7.5$ Hz, 2H, 2CH_2), 3.85 (m, 4H, $2\text{CH}_2\text{N}$), 4.47 (t, $J = 7.2$ Hz, 4H, 2CH_2), 8.76 ppm (s, 1H, pyrimidine). ^{13}C NMR (75 MHz, DMSO) 22.4, 25.8, 26.7, 45.0, 48.7, 100.3, 156.5, 160.5, 166.4, 170.9, 172.5. IR (KBr disc) ν 3005, 2933, 2855, 1653 cm^{-1} . MS (m/z) 289 (M^+).

Fig. 1 Scheme for synthesis compound of 2-(methylthio)-8,9-dihydro-5H-pyrimido[5,4-e]thiazolo[3,2-a]pyrimidin-5-one







Fig. 2 ORTEP view of compound **3**. The displacement ellipsoids are shown at the 50% probability level

Anal. Calcd. for $C_{13}H_{15}N_5OS$ % C, 53.96; H, 5.23; N, 24.20; S, 11.08. Found C, 53.99; H, 5.42; N, 24.57; S, 11.20.

2-(4-Methylpiperidin-1-yl)-7,8-dihydro-5H-pyrimido[5,4-e]thiazolo[3,2-a]pyrimidin-5-one (4c)

White powder, yield =68%, mp. = 200–202 °C, 1H NMR (300 MHz, $DMSO-d_6$) δ 0.93 (d, J = 5.7 Hz 3H, CH_3), 1.08 (m, 2H, CH_2) 1.72 (m, 3H, CH_2 and CH), 2.98 (t, J = 12 Hz, 2H aqatorial, CH_2), 3.57 (t, J = 7.5 Hz, 2H, CH_2), 4.46 (t, J = 7.2 Hz, 2H, CH_2), 4.76 (m, axial 2H, CH_2N), 8.75 ppm (s, 1H, pyrimidine). ^{13}C NMR (75 MHz, $DMSO$) 22.0, 26.7, 30.8, 34.0, 44.3, 48.7, 100.4, 156.5, 160.5, 161.2, 166.5, 170.9. IR (KBr disc) ν 3003, 2950, 2911, 2865, 1668, 1610 cm^{-1} . MS (m/z) 303 (M^+). Anal. Calcd. for

Fig. 3 Packing of compound **3** viewed down the c axis



$C_{14}H_{17}N_5OS$ % C, 55.43; H, 5.65; N, 23.08; S, 10.57 Found C, 55.59; H, 5.55; N, 23.34; S, 10.25.

2-Morpholino-7,8-dihydro-5H-pyrimido[5,4-e]thiazolo[3,2-a]pyrimidin-5-one (4d)

White powder, yield =79%, mp = 285–290 °C, 1H NMR (300 MHz, $DMSO-d_6$) δ 3.35 (t, J = 7.5, 2H, CH_2), 3.68 (t, 4H, J = 5.1 Hz, 2 CH_2N), 3.86(m, 4H, 2 CH_2O), 4.49 ppm (t, 2H, J = 7.5, CH_2); 8.81 ppm (s, 1H, pyrimidine). ^{13}C NMR (75 MHz, $DMSO$) 26.7, 44.5, 48.7, 66.3, 101.0, 151.4, 156.5, 160.6, 166.5, 171.2. IR (KBr disc) ν 3182, 3076, 2962, 2921, 2859, 1705, 1660 cm^{-1} . MS (m/z) 291 (M^+). Anal. Calcd. for $C_{12}H_{13}N_5O_2S$ % C, 49.47; H, 4.50; N, 24.04; S, 11.00. Found C, 49.41; H, 4.72; N, 24.26; S, 11.16.


2-(4-Methylpiperazin-1-yl)-7,8-dihydro-5H-pyrimido[5,4-e]thiazolo[3,2-a]pyrimidin-5-one (4e)

White powder, yield =68%, mp = 249–250 °C, 1H NMR (300 MHz, $DMSO-d_6$) δ 2.23 (s, 3H, CH_3), 2.39 (m, 4H, CH_2-N), 3.58 (t, J = 7.5 Hz, 2H, CH_2), 3.78 (m, 4H, 2 CH_2N), 4.49 (t, J = 7.5 Hz, 2H, CH_2), 8.79 ppm (s, 1H, pyrimidine). ^{13}C NMR (75 MHz, $DMSO$) 26.5, 44.8, 48.7, 51.9, 52.5, 100.9, 156.5, 160.5, 161.3, 166.3, 171.0. IR (KBr disc) ν 3015, 2949, 2864, 2798, 1640, 1608 cm^{-1} . MS (m/z) 304 (M^+). Anal. Calcd. for $C_{13}H_{16}N_6OS$ % C, 51.30; H, 5.30; N, 27.61; S, 10.53 Found C, 51.63; H,5.50; N, 27.35; S, 10.37.

2-(4-Ethylpiperazin-1-yl)-7,8-dihydro-5H-pyrimido[5,4-e]thiazolo[3,2-a]pyrimidin-5-one (4f)

White powder; yield: 78%; mp = 246–248 °C; 1H NMR (300 MHz, , $DMSO-d_6$): δ 1.04 (t, J = 7.2 Hz, 3H, CH_3),

Fig. 4 Packing of compound **3** viewed approximately along (110)



2.37 (q, $J = 7.2$ Hz, 2H, CH₂), 2.45 (m, 4H, CH₂-N), 3.58 (t, 2H, $J = 7.2$ Hz, CH₂-N), 3.87 (m, 4H, CH₂-N), 4.49 (t, 2H, $J = 7.2$ Hz, CH₂), 8.79 (s, 1H, pyrimidine). ¹³C NMR (75 MHz, DMSO) 12.3, 26.7, 44.1, 48.7, 51.9, 52.5, 100.8, 156.5, 160.5, 161.3, 166.5, 171.1. IR (KBr disc) ν 3019, 2966, 2937, 2831, 1652, 1609 cm⁻¹. MS (m/z) 318 (M⁺). Anal. Calcd. for C₁₄H₁₈N₆OS % C, 52.81; H, 5.70; N, 26.40; S, 10.07 Found C, 52.72; H, 5.75; N, 26.25; S, 10.12.

Results and Discussion

Chemistry

The presence of two electron-enriched positions in 2-aminothiazoline ring **1** was led to the reaction of this compound with electrophiles either at the exocyclic or endocyclic nitrogen atom depending on the electrophile and reaction conditions [29, 30]. Furthermore, ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate **2**, which was prepared according to the reported procedure [31], possesses two possible leaving groups, namely Cl and OEt, in which the chlorine atom has been reported to be more reactive than ethoxy moiety [32, 33].

Treatment of **1** with **2** in the presence of Et₃N in CH₃CN may lead to the synthesis of two possible regioisomers **3** and **3'** as depicted in Fig. 1. The experimental and spectral data

showed the formation of only one product with no producing any isolable intermediate. The ¹H NMR spectrum of the product displayed a singlet signal at δ 2.51 ppm for the methyl group, two triplet signals at δ 3.64 and 4.58 for the hydrogens of thiazoline ring and a sharp singlet signal at 8.98 ppm belonging to the hydrogen of the pyrimidine moiety. The ¹³C NMR spectrum also clearly showed nine resolved signals for the corresponding carbons of the compound. The IR spectrum of the product did not exhibit any bands of the starting materials (NH₂ and ester groups at 3389, 3419 and 1734, respectively) and the mass spectrum also showed the molecular ion peak at m/z 252 (M⁺) indicating the molecular formula of C₉H₈N₄OS₂.

The ambiguity in the structure of the product can be clearly resolved through single crystal X-ray analysis (deposition no. CCDC 1442522) (Figs. 2, 3 and 4).

The single crystal X-ray crystallographic data clearly demonstrates the occurrence of nucleophilic substitution on precursor **2** with 4,5-dihydrothiazol-2-amine **1** through path **I** in Fig. 1 along with the subsequent cyclization reaction to give product **3**.

Upon on the regiochemistry of the product, it appears that the endocyclic amino group of 2-aminothiazole **1** is more nucleophilic than the other amino group and attacks the more electrophilic C-Cl bond on precursor **2** which is followed by an intramolecular acyl nucleophilic substitution on COOEt

Fig. 5 Scheme for synthesis derivatives of 2-amino-8,9-dihydro-5H-pyrimido[5,4-*e*]thiazolo[3,2-*a*]pyrimidin-5-one





Fig. 6 UV/Vis Absorption spectrum of compound **4c** in dilute CH₃CN solution (2×10^{-5} M)



fragment to form the final product **3**. Then, the treatment of compound **3** with various cyclic secondary amines afforded the corresponding products **4a–f** (Fig. 5).

The structures of compounds **4a–f** have been confirmed by their spectral data. For example, the ¹H NMR spectrum of **4d** showed two triplet signals at δ 3.68 and 3.86 ppm corresponded to the hydrogens of the morpholine moiety, two triplet signals at δ 3.35 ppm and 4.49 ppm for the hydrogens of the thiazoline core and a sharp singlet peak at 8.81 ppm assigned to the hydrogen of the pyrimidine core. The ¹³C NMR spectrum clearly showed four resolved signals at 26.8, 44.5, 48.7 and 66.3 ppm for the aliphatic carbons of compound **4d** and the other six signals at 101.0, 151.4, 156.5, 160.6, 166.5, 171.2 ppm were assigned to the aromatic carbons. The mass spectrum of compound **4d** also showed the molecular ion peak at m/z 291 (M^+) indicating the molecular formula of C₁₂H₁₃N₅O₂S.

Photophysical Study

The design and synthesis of selective and sensitive compounds containing the pyrimidine moiety with fluorescent probes are attractive research topics in the fields of optoelectronics [34], chemosensors and molecular imaging owing to their biological and environmental interest [35, 36]. Fluorescent probes are the important instrumentation in gaining insight into cellular and bacterial environments [37, 38], and fluorescence spectroscopy is one of the most useful techniques to probe the binding of liposomes to proteins, DNA, and other biomolecules in chemical biology [39, 40]. Herein, we describe the evaluation of these new fluorescent pyrimidine analogs and provide their structure-photophysical properties relationships.

The absorption spectrum of **4c** was scanned in CH₃CN (5×10^{-5} M) and shown in Fig. 6. The wavelengths of maximum absorption (λ_{max}) were in 275 and 340 nm but the highest emission was observed when the compound was excited in 340 nm.

All the absorption and emission spectra of compounds **4a–f** were recorded in CH₃CN, and their λ_{max} and λ_{flu} values were compiled in Table 1.

Values of the extinction coefficient (ϵ) were calculated as the slope of the plot of absorbance *vs.* concentration and had a precision on the order of 5%. The fluorescence quantum yield (Φ) which is the ratio of photons absorbed to photons emitted through fluorescence relative to fluorescein as the reference compound were calculated according to the literature [41]. (Table 1) Compounds **4a–d** exhibited moderately good fluorescence quantum yields. The highest value was obtained for compound **4c** ($\Phi = 0.80$). The compounds under this study exhibited the Stokes shifts ranging from 70 to 95 nm that was calculated from the difference between absorption and emission maxima in cm^{-1} [42].

Photophysical data in Table 1 demonstrated that all compounds were neutral, uncharged, highly fluorescent molecules that were absorbed with high extinction coefficients and emitted at around 410–425 nm. Compounds like biogenic amines are markers for many processes, e.g. recognition of cancer, so that their detection and determination are important [43, 44]. Amines which do not possess an aromatic system can not be detected directly by UV absorption or fluorescence. For


Table 1 Spectroscopic Properties of Products **4a–f** in CH₃CN

Compound	λ_{abs} [nm]	$\epsilon \times 10^{-3}$ [$M^{-1} \text{cm}^{-1}$] ^a	λ_{flu}	Φ ^b	Stokes shift
4a	338	7.55	415	0.70	77
4b	332	8.00	415	0.59	83
4c	340	11.78	410	0.80	70
4d	330	7.85	425	0.52	95
4e	336	11.21	415	-	79
4f	336	7.83	425	-	89

^a Extinction coefficient.

^b Quantum yield of fluorescein in MeOH as standard ($\Phi = 0.95$) [41].

Fig. 7 Emission spectrum of compounds **4a–f** at λ_{ex} 330–340 nm in dilute CH_3CN solution (2×10^{-7} M)




determination of these compounds, especially at low concentrations, many fluorogenic reagents have been developed [45–47]. Moreover, the known fluorescence and pharmacological properties of pyrimidine [48, 49] and thiazole moieties [50–52] as well as the factors promoting proliferation in the biological and photophysical properties and possible relationship between these substances [53] were persuaded us to synthesize thiazolopyrimidine derivatives and study their fluorescence properties. For this purpose, the thiomethyl derivative **3** was converted into products **4a–f**, and speculates that the presence of amino group at the 2-position in pyrimidothiazolopyrimidine plays an important role in the aforementioned strong fluorescence. Compounds **4a–d**, which have morpholine, pyrrolidine, piperidine or 4-methylpiperidine group at the 2-position of the pyrimidine ring, showed stronger fluorescence intensity than did the precursor **3** with methylsulfanyl group. Compounds **4e** and **4f** showed very weak fluorescence intensities. (Fig. 7) This could

mean that a new or extended planar system with enhanced delocalization of π -bonding has been formed.

The emission spectra of chemical compounds can be affected by the medium and they can bring about a change in the position, intensity, and shape of absorption bands [54]. Photophysical properties of **4c** have been studied in a number of organic solvents and H_2O . Fig. 8 shows the emission spectra of **4c** in CHCl_3 , DMF, THF, MeCN, MeOH, EtOH, and H_2O . The fluorescence intensity maxima were found to vary with the nature of the solvent which can be attributed to solvatochromic properties [55]. As can be seen, aprotic solvents such as CHCl_3 , DMF, THF and MeCN showed the higher emission value in comparison with the protic ones. The aprotic solvents do not have hydrogen bond with the solute and the spectrum of the solute closely approximates the spectrum that would be produced in the gaseous state, in which fine structure is often observed. In protic solvents, hydrogen bond forms a solute-solvent complex and the fine structure may disappear [56].

Fig. 8 Fluorescence intensity of a solution of compound **4c** (2×10^{-7} M) in the solvents DMF, CHCl_3 , CH_3CN , THF, EtOH, MeOH and H_2O at λ_{ex} = 340 nm



Conclusion

In summary, we have described the synthesis of various derivatives of the new heterocyclic system, pyrimido[5,4-*e*]thiazolo[3,2-*a*]pyrimidin-5-one via sequential treatment of ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate **1** with 4,5-dihydrothiazol-2-amine **2** and subsequently with secondary amines to obtain products **4a–f**. An account on the single crystal X-ray analysis of the product **3** along with the photophysical properties of the corresponding substituted derivatives **4a–f** was given. Due to their interesting fluorescence properties, these new heterocyclic pyrimido[5,4-*e*]thiazolo[3,2-*a*]pyrimidine derivatives can be used as fluorescent markers and probes for studies in biochemistry and pharmacology.

Acknowledgements The authors gratefully acknowledge Ferdowsi University of Mashhad for financial support of this project. (3/25439). JTM acknowledges the support of the NSF-MRI program (grant No. 1228232) for the purchase of the diffractometer and Tulane University for support of the Tulane Crystallography Laboratory.

References

- Al-Thebeiti MS (2001) Synthesis of some new derivatives of thiazolo-[3,2-*a*]pyrimidine-3,5,7(2H)-trione of potential biological activity. *Boll Chim Farm* 140:221–223
- Shigeta S, Mori S, Watanabe F, Takahashi K, Nagata T, Koike N, Wakayama T, Saneyoshi M (2002) Synthesis and antiherpesvirus activities of 5-alkyl-2-thiopyrimidine nucleoside analogues. *Antivir Chem Chemother* 13:67–82
- Abdel-Rahman R, El-Mahdy K (2012) Biological evaluation of pyrimidopyrimidines as multi-targeted small molecule inhibitors and resistance modifying agents. *Heterocycles* 85:2391–2414
- Curtin NJ, Barlow HC, Bowman KJ, Calvert AH (2004) Resistance-modifying agents. 11. ¹Pyrimido[5,4-*d*]pyrimidine modulators of antitumor drug activity. Synthesis and structure–activity relationships for nucleoside transport inhibition and binding to α_1 -acid glycoprotein. *J Med Chem* 47:4905–4922
- Krueger AC, Madigan DL, Beno DW, Betebenner DA, Carrick R, Green BE, He W, Liu D, Maring CJ, McDaniel KF, Mo H, Molla A, Motter CE, Pilot-Matias TJ, Tufano MD, Kempf DJ (2012) Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives. *Bioorg Med Chem Lett* 22:2212–2215
- Sharma P, Rane N, Gurram VK (2004) Synthesis and QSAR studies of pyrimido[4,5-*d*]pyrimidine-2,5-dione derivatives as potential antimicrobial agents. *Bioorg Med Chem Lett* 14:4185–4190
- Sharma P, Rane N, Pandey P (2006) Synthesis and evaluation of antimicrobial activity of novel hydrazino and *N*-benzylidenehydrazino-substituted 4,8-dihydro-1*H*,3*H*-pyrimido[4,5-*d*]pyrimidin-2,7-dithiones. *Arch Pharm* 339:572–578
- de la Cruz JP, Ortega G, Sanchez de la Cuesta F (1994) Differential effects of the pyrimido-pyrimidine derivatives, dipyridamole and mopidamol, on platelet and vascular cyclooxygenase activity. *Biochem Pharmacol* 47:209–215
- Rewcastle GW, Bridges AJ, Fry DW, Rubin JR, Denny WA (1997) Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-*d*]pyrimidines designed as inhibitors of the epidermal growth factor receptor. *J Med Chem* 40:1820–1826
- Fry DW, Becker MA, Switzer RL (1995) Inhibition of human 5-phosphoribosyl-1-pyrophosphate synthetase by 4-amino-8-(beta-D-ribofuranosylamino)-pyrimido[5,4-*d*]pyrimidine-5'-monophosphate: evidence for interaction at the ADP allosteric site. *Mol Pharma* 47:810–815
- Eynde JJV, Hecq N, Kataeva O, Kappe CO (2001) Microwave-mediated regioselective synthesis of novel pyrimido[1,2-*a*]pyrimidines under solvent-free conditions. *Tetrahedron* 57:1785–1791
- Pratap R, Kushwaha SP, Goel A, Ram VJ (2007) An efficient synthesis of (*E*)-(2-arylpyrazino[1,2-*a*]pyrimidine-4-ylidene)acetonitriles and cyanomethyl appended pyrimidines. *Tetrahedron Lett* 48:549–553
- Xiang J, Geng C, Yi L, Dang Q, Xu B (2011) Synthesis of highly substituted 2,3-dihydropyrimido[4,5-*d*]pyrimidin-4(1*H*)-ones from 4,6-dichloro-5-formylpyrimidine, amines and aldehydes. *Mol Divers* 15:839–847
- Walters I, Austin C, Austin R, Bonnert R, Cage P, Christie M, Ebdon M, Gardiner S, Grahames C, Hill S, Hunt F, Jewell R, Lewis S, Martin I, Nicholls D, Robinson D (2008) Evaluation of a series of bicyclic CXCR2 antagonists. *Bioorg Med Chem Lett* 18:798–803
- Mohamed SF, Flefel EM, Amr AE, Abd-El-Shafy DN (2010) Anti-HSV-1 activity and mechanism of action of some new synthesized substituted pyrimidine, thiopyrimidine and thiazolopyrimidine derivatives. *Eur J Med Chem* 45:1494–1501
- Campaigne E, Huffman JC, Selby TP (1979) Synthesis and crystal structure of a covalently hydrated 8-thia-1,4-diazacycl[3.3.2]azine. *J Heterocycl Chem* 16:725–729
- Pashkurov NG, Reznik VS (1967) Reactions of 2-mercaptopyrimidines with α , ω -bromochloro- and α , ω -bromofluoroalkanes. *Chem Heterocycl Compd* 3:846–847
- Shaw G, Warrener RN, (1959) Purines, pyrimidines, and glyoxalines. Part XI. Some oxazolidino- and thiazolidino-[2: 3-*a*]pyrimidines, and a synthesis of thymidine. *J Chem Soc* 50–55. doi:10.1039/JR9590000050
- Brown GR, Dyson WR (1971) Synthesis and reactions of thiazolidino[3,2-*a*]pyrimidines. *J Chem Soc C*:1527–1529
- Kato T, Katagiri N, Izumi U, Miura Y, Yamazaki T, Hirai Y (1981) Studies on ketene and its derivatives. CIII. Synthesis of fused 4-pyrimidones and their photoreactions. *Heterocycles* 15:399–402
- Al-Jallo HN, Muniem MA (1978) Synthesis and nuclear magnetic resonance spectra of fused pyrimidines. *J Heterocycl Chem* 15:849–853
- Glennon RA, Bass RG, Schubert E (1979) Alkylation studies on 6-ethyl-2,3-dihydrothiazolo-[3,2-*a*] pyrimidine-5,7-diones. *J Heterocycl Chem* 16:903–907
- Bakavoli M, Eshghi H, Azizolahy H, Saberi S, Bazrafshan F (2014) One-pot, procedure for the preparation of some thiazino[2,3-*b*]quinoxaline derivatives. *J Chem Res* 38:189–191
- Bakavoli M, Rahimizadeh M, Shiri A, Eshghi H, Pordeli P, Pordel M, Nikpour M (2011) Synthesis and antibacterial evaluations of new pyridazino[4,3-*e*][1,3,4]oxadiazines. *J Heterocycl Chem* 48:149–152
- Asghari T, Bakavoli M, Eshghi H, Saberi S, Ebrahimpour Z (2015) Synthesis of 5,5'-(ethane-1,2-diyl)bis(3-((5-bromo-6-methyl-2-tertiaryaminopyrimidin-4-yl)thio)-4*H*-1,2,4-triazol-4-aminos) and their novel bis-cyclized products, 1,2-bis(pyrimido[5,4-*e*][1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazin-3-yl)ethane, as potential inhibitors of 15-lipoxygenase. *J Het Chem* 53:403–407
- Mohadeszadeh M, Rahimizadeh M, Eshghi H, Shiri A, Gholizadeh M, Shams A (2015) Synthesis and spectral characteristics of novel fluorescent dyes based on pyrimido[4,5-*d*][1,2,4]triazolo[4,3-*a*]pyrimidine. *Helvetica Chimica Acta* 98:474–481
- Bruker (2004) APEX2, SAINT, SADABS, SHELXT. Bruker AXS Inc; Madison, Wisconsin, USA

28. Sheldrick GM (2015) SHELXT— Integrated space-group and crystal-structure determination. *Acta Crystallogr Sect A* 71:3–8
29. Miloudi A, El Abed D, Boyer G, Finet JP, Galy JP, Siri D (2004) Reactivity of 2-aminothiazole and 2- or 6-aminobenzothiazole derivatives towards the triphenylbismuth diacetate/catalytic copper diacetate phenylation system. *Eur J Org Chem* 7:1509–1516
30. Jin L, Song B, Zhang G, Xu R, Zhang S, Gao X, Hu D, Yang S (2006) Synthesis, X-ray crystallographic analysis, and antitumor activity of *N*-(benzothiazole-2-yl)-1-(fluorophenyl)-*O*,*O*-dialkyl- α -aminophosphonates. *Bioorg Med Chem Lett* 16:1537–1543
31. Muller E, Roch J, Narr B, Haarmann W (1974) pyrazolo[3,4-*d*]pyrimidin-3-one. Ger. Offen. 2430644, Chem. Abstr. 1976, 84, 135708s.
32. Irie O, Yokokawa F, Ehara T, Iwasaki A, Iwaki Y, Hitomi Y, Konishi K, Kishida M, Toyao A, Masuya K, Gunji H, Sakaki J, Iwasaki G, Hirao H, Kanazawa T, Tanabe K, Kosaka T, Hart TW, Hallett A (2008) 4-amino-2-cyanopyrimidines: novel scaffold for nonpeptidic cathepsin S inhibitors. *Bioorg Med Chem Lett* 18: 4642–4646
33. Ryckmans T, Aubdool AA, Bodkin JV, Cox P, Brain SD, Dupont T, Fairman E, Hashizume Y, Ishii N, Kato T, Kitching L, Newman J, Omoto K, Rawson D, Strover J (2011) Design and pharmacological evaluation of PF-4840154, a non-electrophilic reference agonist of the TrpA1 channel. *Bioorg Med Chem Lett* 21:4857–4859
34. Achelle S, Plé N (2012) Pyrimidine ring as building block for the synthesis of functionalized π -conjugated materials. *Curr Org Synth* 9:163–187
35. Deligeorgiev TG, Gadjev NI, Vasilev AA, Maximova VA, Timcheva II, Katerinopoulos HE, Tsikalas GK (2007) Synthesis and properties of novel asymmetric monomethine cyanine dyes as non-covalent labels for nucleic acids. *Dyes Pigments* 75:466–473
36. Ho YW, Yao WH (2009) The synthesis and spectral characteristics of novel 6-(2-substituted-1,3,4-oxadiazol-5-yl)-2-phenylthieno[2,3-*d*]pyrimidine fluorescent compounds derived from 5-cyano-1,6-dihydro-4-methyl-2-phenyl-6-thioxopyrimidine. *Dyes Pigments* 82:6–12
37. Zhang J, Campbell RE, Ting AY, Tsien RY (2002) Creating new fluorescent probes for cell biology. *Nat Rev Mol Cell Biol* 3:906–918
38. Lavis LD, Raines RT (2008) Bright ideas for chemical biology. *ACS Chem Biol* 3:142–155
39. Sinkeldam RW, Greco NJ, Tor Y (2010) Fluorescent analogs of biomolecular building blocks: design, properties, and applications. *Chem Rev* 110:2579–2619
40. Phelps K, Morris A, Beal PA (2012) Novel modifications in RNA. *ACS Chem Biol* 7:100–109
41. Würth C, Grabolle M, Pauli J, Spieles M, Resch-Genger U (2013) Relative and absolute determination of fluorescence quantum yields of transparent samples. *Nature Protocols* 8:1535–1550
42. Resch-Genger U, Grabolle M, Cavaliere-Jaricot S, Nitschke R, Nann T (2008) Quantum dots versus organic dyes as fluorescent labels. *Nat Methods* 5:763–775
43. Steinert J, Khalaf H, Keese W, Rimpler M (1996) Sensitive liquid chromatographic determination of hydrophobic primary and secondary amines by derivatization to form highly fluorescent thiazoles. *Anal Chim Acta* 327:153–159
44. Patel BR, Kirschbaum JJ, Poet RBJ (1981) High-pressure liquid chromatography of nadolol and other beta-adrenergic blocking drugs. *Pharm Sci* 70:336–338
45. Khalaf H, Steinert J (1996) Determination of secondary amines as highly fluorescent formamidines by high-performance liquid chromatography. *Anal Chim Acta* 334:45–50
46. Garcia Alvarez-Coque MC, Medina Hernandez MJ, Villanueva Camanas RM (1989) Formation and instability of o-phthalaldehyde derivatives of amino acids. *Anal Biochem* 178:1–7
47. Watanabe Y, Imai K (1982) Pre-column labelling for high-performance liquid chromatography of amino acids with 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole and its application to protein hydrolysates. *J Chromatogr* 239:723–732
48. Zaltzman P (1962) Fluorescence characteristics of purines, pyrimidines, and their derivatives: measurement of guanine in nucleic acid hydrolyzates. *Anal Biochem* 3:49–59
49. Daniels M, Hauswirth W (1971) Fluorescence of the purine and pyrimidine bases of the nucleic acids in neutral aqueous solution at 300 degrees K. *Science* 171:675–677
50. Wolfram S, Würfel H, Habenicht SH, Lembke CH, Richter PH, Birckner E, Beckert R, Pohnert G (2014) A small azide-modified thiazole-based reporter molecule for fluorescence and mass spectrometric detection. *Beilstein J Org Chem* 10:2470–2479
51. Lorena K, Calderón-Ortiz LK, Täuscher E, Bastos EL, Görls H, Weiß D, Beckert R (2012) Hydroxythiazole-based fluorescent probes for fluoride ion detection. *Eur J Org Chem* 2012:2535–2541
52. Täuscher E, Calderón-Ortiz L, Weiß D, Beckert R, Görls H (2011) Bis(4-hydroxythiazoles): novel functional and switchable fluorophores. *Synthesis* 14:2334–2339
53. Hou Z, Zhou N, He B, Yang Y, Yu X (2011) Study on the interaction between thiazolopyrimidine analogues and bovine serum albumin. *Spectrochim Acta A Mol Biomol Spectrosc* 79:1931–1935
54. Marini A, Muñoz-Losa A, Biancardi A, Mennucci B (2010) What is solvatochromism? *J Phys Chem B* 114:17128–17135
55. Reichardt C (1994) Solvatochromic dyes as solvent polarity indicators. *Chem Rev* 94:2319–2358
56. Pavia DL, Lampman GM, Kriz GS (2015) Introduction to spectroscopy, Fourth edn. Cengage Learning, Stamford, pp 403–404